Amikacin-eravacycline combination mediates the synergistic elimination of carbapenem-resistant pathogens via in vitro and in vivo metabolic reprogramming
PLOS Pathogens · 2026
DOI: 10.1371/journal.ppat.1013938 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2026. Verfasst von Xiaoli Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Amikacin, Anti-Bacterial Agents, Tetracyclines. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Medical Foundation, Beijing Life Oasis Public Service Center.
Abstract (Originalsprache)
Carbapenem-resistant (CR) organisms (CRO) have been identified as critical priority pathogens, emphasizing the urgent need for novel therapeutic strategies. Combination therapy emerges as a promising approach to address multidrug-resistant bacterial infections. Here we demonstrate that eravacycline (ERV), in combination with amikacin (AMK), effectively eliminates a panel of clinically isolated CR Escherichia coli , CR Klebsiella pneumoniae , and CR Acinetobacter baumannii . Mechanistically, the AMK-ERV combination enhances bacterial oxidative phosphorylation, leading to an accumulation of reactive oxygen species, which induce oxidative stress and accelerate bacterial cell death. Notably, this combination significantly improves survival rates in mouse models of intra-abdominal infection, demonstrating efficacy against infections induced by CR pathogens. Furthermore, serum metabolomics reveals that the AMK-ERV combination upregulates metabolic pathways of lipids and amino acids. Interestingly, the amino acid methionine significantly enhances the antibacterial activity of ERV against CR pathogens both in vitro and in vivo . Our findings underscore the potential of repurposing AMK in combination with ERV to combat CR pathogens and propose a novel strategy for controlling these infections through the combination of antibiotics with specific metabolites such as methionine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- Microbiology Laboratory, Department of Clinical Laboratory, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China.
ORCID-Profile: Xikang Tang
Förderung
- China Medical Foundation
- Beijing Life Oasis Public Service Center
Zitieren
APA
Yang, X., Chen, Y., Yang, J., Lei, J., Liu, T., Mai, Y., & Tang, X. (2026). Amikacin-eravacycline combination mediates the synergistic elimination of carbapenem-resistant pathogens via in vitro and in vivo metabolic reprogramming. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1013938
Vancouver
Yang X, Chen Y, Yang J, Lei J, Liu T, Mai Y, et al. Amikacin-eravacycline combination mediates the synergistic elimination of carbapenem-resistant pathogens via in vitro and in vivo metabolic reprogramming. PLOS Pathogens. 2026. doi:10.1371/journal.ppat.1013938
BibTeX
@article{Yang2026,
author = {Yang, Xiaoli and Chen, Yili and Yang, Jinmei and Lei, Jiaying and Liu, Tinghua and Mai, Yougang and Tang, Xikang},
title = {Amikacin-eravacycline combination mediates the synergistic elimination of carbapenem-resistant pathogens via in vitro and in vivo metabolic reprogramming},
journal = {PLOS Pathogens},
year = {2026},
doi = {10.1371/journal.ppat.1013938}
}
EUVIMED